使用基于小组的轨迹建模来评估在异形性肺纤维化患者中对宁泰达尼布的药物坚持
Mona Nili1, Andrew J Epstein2, Dominic Nunag2
1Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA. mona.nili@boehringer-ingelheim.com.
基于小组的轨迹模型在异常性肺纤维化患者中确定了五种不同的宁泰达尼布坚持模式. 老年和女性性别与较差的坚持有关,使个性化干预成为可能.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 坚持抗纤维素药物治疗对于异形性肺纤维化 (IPF) 管理至关重要.
- 传统的坚持度指标,如覆盖日数比例 (PDC),无法捕捉时间坚持的模式.
- 基于组的轨迹建模 (GBTM) 提供了一种方法来分析随着时间的推移的坚持.
研究的目的:
- 评估使用GBTM的IPF患者的宁泰丹尼布粘附轨迹.
- 识别与不同坚持模式相关的患者特征.
主要方法:
- GBTM应用于1,798名IPF患者的月度PDC数据,这些患者开始使用nintedanib.
- 使用了2014-2018年的医疗保险索赔和入学数据.
- 分数多项逻辑模型量化了患者特征和坚持群体之间的关联.
主要成果:
- 确定了五种不同的任天堂的坚持轨迹:高,中等,高-然后-贫穷,延迟-贫穷和早期-贫穷的坚持.
- 与不良坚持相关的因素包括年龄较大,女性性别,非白人种族/种族,以及较高的基线药物计数.
- 43.1%的患者保持了高度的坚持.
结论:
- 在IPF患者中,GBTM有效地识别了多样化的宁泰达尼布坚持模式.
- 了解这些轨迹和相关的患者特征,可以进行更个性化的干预.
- 这种方法提供了超越传统的遵守指标的可操作的见解.
更多相关视频
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
06:52Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
相关概念视频
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Drug Therapy
Antianxiety Medications
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
